ABSTRACT

Introduction Hemophilia is the most prevalent severe genetic hemorrhagic disease. Hemophilia A and B both are attributed to insufficiencies or malfunctions of the corresponding factor VIII and factor IX proteins. The conditions are distinguished by protracted and copious hemorrhage, subsequent to minor trauma or occasionally manifesting independently. Hemophilia C is an additional rare disorder caused by an insufficiency of coagulation factor XI. The most prevalent clinical presentation of severe hemophilia is hemarthrosis. In the absence of proper management, even subclinical hemarthrosis has the potential to progress to hemophilic arthropathy, an incapacitating condition marked by joint degeneration, persistent discomfort and a diminished standard of living; ultimately, surgical treatments becomes necessary. Out of all joints, knee joints are most commonly affected joint in the hemophilia patients as it bears the weight of the body. Presence of advancements in the modern system of medicine, chronic arthropathy continues to be a substantialconcern. Ayurveda has a good command over this symptoms which resemble’s to vatarakta, hence play a vital role in hemophilic arthropathy. Methods: We devised a prospective, open-label, single-arm clinical trial involving participants who volunteered to be screened as part of the project. Constant monitoring with respect to adverse circumstances maintained for the duration of the study. Participants will be monitored on the first, thirty and forty-fifth day. The duration of the intervention is 30 days, an additional 15 days are allocated for follow-up. Inclusion Criteria is: Age between 12 – 40 years & Stage -2/3/4 arthritic changes present in the knee joint. & The patient suffering from moderate to severe Hemophilia (A or B) from factor assay (8 or 9) or having valid registered id card from Hemophilia society or any government hospital showing factor percentage. Source of patients will be from CARI punjabi bagh, LNJP Hospital Delhi and from hemophilia societies. Result & Conclusion: As the research remains ongoing, the definitive outcomes and conclusions have not yet been ascertained. IEC has been approved on 11.12.2023 and CTRI/2024/01/061535 [Registered on: 16/01/2024]. Keywords: Hemophilia, Hemarthrosis, Hemophilic arthropathy, Dashang Lepa, Pinda tail, Praval bhasma, Lakshadi guggulu
Publication date: 01/07/2025

https://ijbpas.com/pdf/2025/July/MS_IJBPAS_2025_9245.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.7.9245